CSIMarket
 


Eli Lilly And Company  (LLY)
Other Ticker:  
 
 

LLY's Net Income Growth by Quarter and Year

Eli Lilly And's Net Income results by quarter and year




LLY Net Income (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December 1,937.70 1,726.10 2,116.80 1,495.70
III Quarter September 1,451.70 1,110.10 1,208.40 1,253.90
II Quarter June 952.50 1,390.20 1,412.00 1,327.20
I Quarter March 1,902.90 1,355.30 1,456.50 4,241.60
FY   6,244.80 5,581.70 6,193.70 8,318.40



LLY Net Income fourth quarter 2022 Y/Y Growth Comment
Eli Lilly And Company achieved in the fourth quarter 2022, above Company average Net Income increase of 12.26% year on year, to $ 1,937.70 millions.

Looking into fourth quarter 2022 results within Major Pharmaceutical Preparations industry 15 other companies have achieved higher Net Income growth. While Eli Lilly And Company' s Net Income growth of 12.26% ranks overall at the positon no. 894 in the fourth quarter 2022.




LLY Net Income ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December 12.26 % -18.46 % 41.53 % 383.26 %
III Quarter September 30.77 % -8.13 % -3.63 % 9.08 %
II Quarter June -31.48 % -1.54 % 6.39 % -
I Quarter March 40.4 % -6.95 % -65.66 % 248.41 %
FY   11.88 % -9.88 % -25.54 % 244.23 %

Financial Statements
Eli Lilly And's fourth quarter 2022 Net Income $ 1,937.70 millions LLY's Income Statement
Eli Lilly And's fourth quarter 2021 Net Income $ 1,726.10 millions Quarterly LLY's Income Statement
New: More LLY's historic Net Income Growth >>


LLY Net Income (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December 33.48 % 55.49 % 75.17 % 19.28 %
III Quarter September 52.41 % -20.15 % -14.42 % -5.52 %
II Quarter June -49.94 % 2.58 % -3.06 % -68.71 %
I Quarter March 10.24 % -35.97 % -2.62 % 1270.47 %
FY (Year on Year)   11.88 % -9.88 % -25.54 % 244.23 %




Net Income fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #16
Healthcare Sector #59
Overall #894

Net Income Y/Y Growth Statistics
High Average Low
125.15 % 3.82 % -36.59 %
(Mar 31 2019)   (Sep. 30. 2008)
Net Income fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #16
Healthcare Sector #59
Overall #894
Net Income Y/Y Growth Statistics
High Average Low
125.15 % 3.82 % -36.59 %
(Mar 31 2019)   (Sep. 30. 2008)

Net Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Eli Lilly And's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
1270.47 % 26.1 % -84.86 %
(Mar 31 2019)  


LLY's IV. Quarter Q/Q Net Income Comment
Eli Lilly And Company achieved in the IV. Quarter 2022 above company average sequential Net Income jump of 33.48%, to $ 1,937.70 millions, from $1,451.70 millions in the third quarter.

Within Major Pharmaceutical Preparations industry 9 other companies have achieved higher Net Income quarter on quarter growth. While Eli Lilly And's Net Income growth quarter on quarter, overall rank is 447.


Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #10
Healthcare Sector #38
Overall #447
Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #10
Healthcare Sector #38
Overall #447
Net Income Q/Q Growth Statistics
High Average Low
1270.47 % 26.1 % -84.86 %
(Mar 31 2019)  


LLY's IV. Quarter Q/Q Net Income Comment
Eli Lilly And Company achieved in the IV. Quarter 2022 above company average sequential Net Income jump of 33.48%, to $ 1,937.70 millions, from $1,451.70 millions in the third quarter.

Within Major Pharmaceutical Preparations industry 9 other companies have achieved higher Net Income quarter on quarter growth. While Eli Lilly And's Net Income growth quarter on quarter, overall rank is 447.


Eli Lilly And's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
Cumulative Net Income 12 Months Ending $ 6,244.80 $ 6,033.20 $ 5,691.60 $ 6,129.30 $ 5,581.70
Y / Y Net Income Growth (TTM) 11.88 % 1.02 % -6.24 % 0.6 % -9.88 %
Year on Year Net Income Growth Overall Ranking # 811 # 1213 # 1357 # 446 # 1376
Seqeuential Net Income Change (TTM) 3.51 % 6 % -7.14 % 9.81 % -6.54 %
Seq. Net Income Growth (TTM) Overall Ranking # 894 # 205 # 1251 # 835 # 263




Cumulative Net Income growth Comment
Although Eli Lilly And's Annual Net Income growth year on year were below company's average 39.32% , Net Income announced in the Dec 31 2022 period, show improvement in Net Income trend, to cumulative trailing twelve month growth of 11.88% year on year, from 1.02% in Sep 30 2022.

In the Healthcare sector 61 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 811, from total ranking in previous quarter at 1213.

Net Income TTM Q/Q Growth Statistics
High Average Low
125.15 %
3.82 %
-36.59 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 16
Healthcare Sector # 62
Overall # 811

Net Income TTM Y/Y Growth Statistics
High Average Low
1484.58 %
39.32 %
-79.77 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 16
Sector # 59
S&P 500 # 894
Cumulative Net Income growth Comment
Although Eli Lilly And's Annual Net Income growth year on year were below company's average 39.32% , Net Income announced in the Dec 31 2022 period, show improvement in Net Income trend, to cumulative trailing twelve month growth of 11.88% year on year, from 1.02% in Sep 30 2022.

In the Healthcare sector 61 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 811, from total ranking in previous quarter at 1213.

Net Income TTM Q/Q Growth Statistics
High Average Low
125.15 %
3.82 %
-36.59 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 16
Healthcare Sector # 62
Overall # 811

Net Income TTM Y/Y Growth Statistics
High Average Low
1484.58 %
39.32 %
-79.77 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 16
Sector # 59
S&P 500 # 894




Other Net Income Growth
Major Pharmaceutical Preparations Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
LLY's Net Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for LLY's Competitors
Net Income Growth for Eli Lilly And's Suppliers
Net Income Growth for LLY's Customers

You may also want to know
LLY's Annual Growth Rates LLY's Profitability Ratios LLY's Asset Turnover Ratio LLY's Dividend Growth
LLY's Roe LLY's Valuation Ratios LLY's Financial Strength Ratios LLY's Dividend Payout Ratio
LLY's Roa LLY's Inventory Turnover Ratio LLY's Growth Rates LLY's Dividend Comparisons



Companies with similar Net Income jump for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %Net Income for the quarter ending Dec 31 2022
Staar Surgical Company18.92%$ 18.915 millions
Edwards Lifesciences Corporation18.82%$ 18.819 millions
Purple Biotech Ltd 17.83%$ 17.825 millions
United Therapeutics Corporation17.74%$ 17.736 millions
Integra Lifesciences Holdings Corp16.66%$ 16.662 millions
Electromed Inc 16.59%$ 16.587 millions
Mettler toledo International Inc 15.14%$ 15.144 millions
Option Care Health Inc 14.98%$ 14.979 millions
Addus Homecare Corporation13.05%$ 13.049 millions
Eli Lilly And Company12.26%$ 12.259 millions
Resmed Inc 11.48%$ 11.481 millions
Zoetis Inc 11.38%$ 11.380 millions
Check cap Ltd 11.08%$ 11.080 millions
Utah Medical Products Inc10.26%$ 10.261 millions
Exicure Inc 9.92%$ 9.919 millions
Conmed Corporation8.75%$ 8.755 millions
Vascular Biogenics Ltd 7.97%$ 7.968 millions
Vertex Pharmaceuticals Inc6.34%$ 6.335 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com